Translate 
Abstract
Summary This article aims to summarize the highlights of the two largest global congresses of 2024 with respect to gastroesophageal tumors. The triplet chemotherapy combination known as FLOT (5-fluorouracil, leucovorin, oxaliplatin, docetaxel), used as perioperative chemotherapy, was demonstrated to improve overall and disease-free survival in resectable gastroesophageal cancer patients some time ago. Despite being standard for this patient population, many questions for different scenarios remain open: Is FLOT also efficacious in patients with esophageal or gastroesophageal junction adenocarcinoma when compared to neoadjuvant chemoradiotherapy? Is FLOT a feasible chemotherapy option for oligometastatic patients, thereby contributing to the overall survival as “neoadjuvant” treatment before palliative resection? Can the efficacy of FLOT be strengthened by applying additional radiation treatment to patients with gastroesophageal adenocarcinoma? Is FLOT really necessary in the adjuvant setting for all patients, or can the adjuvant treatment be guided based on pathological response rates? These questions were answered to some extent in the ESOPEC and RENAISSANCE trials at the American Society of Clinical Oncology (ASCO) meeting and the TOPGEAR and SPACE-FLOT trials at European Society for Medical Oncology (ESMO) meeting. Many other FLOT-related studies for resectable as well as metastatic gastroesophageal cancer patients are yet to come.
Highlights
The American Society of Clinical Oncology (ASCO) Annual Congress presents a plenary session on Sunday, where usually four selected abstracts among all cancer types—including hematological and pediatric cancers—are presented
If we look at the content of plenary sessions over the last 15 years, we see a broad spectrum of topics spanning from public health issues to hematological diseases
ESOPEC was one of the clinical trials focusing on GE oncology, where the first results were presented as a plenary abstract at ASCO [1, 2]
Summary
The American Society of Clinical Oncology (ASCO) Annual Congress presents a plenary session on Sunday, where usually four (and in some years, five) selected abstracts among all cancer types—including hematological and pediatric cancers—are presented. This event is highly appreciated and eagerly awaited. If we look at the content of plenary sessions over the last 15 years, we see a broad spectrum of topics spanning from public health issues to hematological diseases During this time period, an abstract from the field of gastroesophageal (GE) tumors was presented for the first time at ASCO 2024. This trend of FLOT (5-fluorouracil [FU], leucovorin, oxaliplatin, docetaxel)-related clinical trials answering very relevant daily clinical questions continued with other trials—which will be discussed within the scope of this manuscript—including RENAISSANCE [3, 4], TOPGEAR [5, 6], and SPACE-FLOT [7]
Sign-in/Register to view highlights & summary 
Paper version not known (
Free)
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
